365 Gout and Other Crystal-Associated Arthropathies Flashcards
Focus on gout
Most common early clinical manifestation of gout (H20 C365 P2632)
Acute arthritis
Polarized microscopy findings of synovial fluid in gout (H20 C365 P2632)
Needle-shaped MSU crystals that are brightly birefringent with negative elongation
Synovial fluid leukocyte counts in gout (H20 C365 P2632)
2,000-60,000/uL
Excretion of this amount of uric acud per 24 h on a regular diet suggests overproduction of purine (H20 C365 P2632)
> 800 mg
Ultrasound finding in gout (H20 C365 P2632)
Double contour sign
Therapy for acute gout when NSAIDs, colchicine, and glucocorticoids have failed (H20 C365 P2633)
Daily anakinra
Serum uric acid target during probenecid or allopurinol therapy for gout (H20 C365 P2633)
<6 mg/dL
This serum uric acid level is an indication to start hypouricemic therapy (H20 C365 P2633)
> 535 umol/L (>9 mg/dL)
Uricosuric drugs are indicated for patients with 24 hr excretion if uric acid of: (H20 C365 P2633)
<600 mg
Uricosuric drug that is more effective in patients with CKD (H20 C365 P2633)
Benzbromarone
Uricosuric agent approved only in patients already on a xanthine oxidase inhibitor (H20 C365 P2633)
Lesinurad
The best drug to lower serum urate in patients with renal disease (H20 C365 P2633)
Allopurinol
The best drug to lower serum urate in urate stone formers (H20 C365 P2633)
Allopurinol
Toxicity with allopurinol has been recognized increasingly in patients taking these drugs (H20 C365 P2633)
Thiazide diuretics
Toxicity with allopurinol has been recognized increasingly in patients allergic to: [2] (H20 C365 P2633)
Penicillin, ampicillin